Biomarker Analysis in Post-COVID Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-01

Study Completion Date

2023-04-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache

NCT06132529

Post-Traumatic Headache Healthy

COMPLETED

Long-term Effects of SARS-CoV-2 on the Central Nervous System and One-year Follow-up of "Long COVID-19" Patients

NCT05492292

Long Covid19

UNKNOWN NA

Cognitive Impairment and Fatigue After Mild to Moderate COVID-19

NCT06042530

Post COVID-19 Condition Cognitive Impairment Fatigue, Mental

RECRUITING

Exploring Brain Damages After COVID-19 Infection

NCT04405986

SARS-CoV 2

COMPLETED NA

A Study to Evaluate White Matter Hyperintensities in Migraine

NCT05112289

Migraine Small Vessel Ischemic Disease Multiple Sclerosis

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Measurements of neuronal and glial markers in CSF were performed on a SIMOA analyzer (Quanterix) using the Neurology 4-Plex A (Nf-L, Tau, GFAP, UCH-L1) kit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-COVID-19 Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Persistent post-COVID-19 headache

post-COVID-19 patients with persistent headache

no intervention

Intervention Type OTHER

no intervention

controls

Mild Neuro-COVID-19 patients without persistent headache and other neurological diseases

no intervention

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of COVID, Parkinson's disease, primary headache, Multiples Sclerosis, facial paralysis
* Persistent post-COVID-19 headache after 3 months of infection
* Post COVID-patients without persistent headache
* must be able to perform lumbar puncture